Personalised blueprint of chronic inflammation in health-to-disease transition
Summary
Horizon Europe is the European Union (EU) funding programme for the period 2021 – 2027, which targets the sectors of research and innovation. The programme’s budget is around € 95.5 billion, of which € 5.4 billion is from NextGenerationEU to stimulate recovery and strengthen the EU’s resilience in the future, and € 4.5 billion is additional aid.
Programme Name
Programme Description
Horizon Europe is the European Union (EU) funding programme for the period 2021 – 2027, which targets the sectors of research and innovation. The programme’s budget is around € 95.5 billion, of which € 5.4 billion is from NextGenerationEU to stimulate recovery and strengthen the EU’s resilience in the future, and € 4.5 billion is additional aid.
Call
Detailed Call Description
The proposals should address several of the following areas:
- Integrate state-of-the-art knowledge and data from suitable human studies (i.e. medical/clinical, well-being, life-style etc.) to identify actionable factors linking chronic systemic and/or local inflammation to the health-to-disease transition. Take stock of omics (i.e. genomics, metabolomics, nutrigenomics, microbiomics etc.), of dynamic measurements of the health and well-being status, and of data-driven analytical tools in order to identify biomarkers and other health indicators linked to the health-to-disease transition.
- Understand at the systems-level the human biology and physiology underlying chronic inflammation in connection to the tissues/organ dysregulation, organ cross-talk and homeostasis breakdown triggering the health-to-disease transition, taking into account the person’s genotype, phenotype, medical history, nutritional and well-being status, life-style and/or occupational/environmental/life stressors.
- Develop and deploy robust sensors, devices and/or mobile apps and other innovative technologies to monitor dynamically the individual’s health status and to identify objective indicators of chronic inflammation correlative to the health-to-disease transition.
- Implement proof-of-concept human studies to assess the beneficial effect of diverse prevention and/or interventions strategies with the aim to demonstrate improved health outcomes.
- Test suitable interventions with the aim to demonstrate the reduction and/or reversion of the pre-disease state linked to chronic systemic and/or local inflammation.
The topic does not exclude any diseases/disorders. Proposals should adopt a patient-centred approach to inform and empower patients, promote a culture of dialogue and openness between health professionals, patients and their families, and unleash the potential for social innovation.
Financing percentage by EU or other bodies / Level of Subsidy or Loan
100%
Contribution per project: €7,00 million
Programme Category
EU Competitive ProgrammesTotal Budget
€50,00 millionThematic Categories
- Health
- Research, Technological Development and Innovation
Eligibility for Participation
- State-owned Enterprises
Call Opening Date
06/10/2021Call Closing Date
21/04/2022National Contact Point(s)
Research and Innovation Foundation
29a Andrea Michalakopoulou, 1075 Nicosia
P.O.Box 23422, 1683 Nicosia
Telephone: +357 22205000
Email Address: support@research.org.cy
Website: https://www.research.org.cy/en/
Mr Marinos Fotiadis
Contact Phone: 22 205 048
E-mail: mphotiades@research.org.cy
Website: https://www.research.org.cy/
Dr Ioannis Theodorou
Contact Phone: 22 205 038
E-mail: itheodorou@research.org.cy
Website: https://www.research.org.cy/
(Publish Date: 23/11/2021-for internal use only)
EU Contact Point
European Commission, Directorate-General for Research and Innovation
https://ec.europa.eu/info/departments/research-and-innovation_en#contact
